Urinary Metabolic Signature of Primary Aldosteronism: Gender and Subtype‐Specific Alterations. Issue 4 (4th January 2019)

• Record Type: Journal Article
• Authors: Lana, Alessandro; Alexander, Keisha; Castagna, Annalisa; D'Alessandro, Angelo; Morandini, Francesca; Pizzolo, Francesca; Zorzi, Francesco; Mulatero, Paolo; Zolla, Lello; Olivieri, Oliviero
• Is Part Of: Proteomics. Volume 13:Issue 4(2019)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2019-01-04
• Subjects: aldosterone‐producing adenoma -- aldosterone‐to‐renin ratio -- hypertension -- primary aldosteronism -- urinary metabolomics; Proteomics -- Periodicals; 572.605
• DOI: 10.1002/prca.201800049
• Languages: English
• ISSNs: 1862-8346

Abstract

Abstract : Purpose: The current clinical investigation for primary aldosteronism (PA) diagnosis requires complex expensive tests from the initial suspicion to the final subtype classification, including invasive approaches; therefore, appropriate markers for subtype definition are greatly desirable. The present study performs a metabolomics analysis to further examine specific molecular signatures of PA urines Experimental design: The study considered PA subtype and gender‐related differences using two orthogonal advanced UHPLC‐MS metabolomics approaches. Patients with essential hypertension ( n = 36) and PA ( n = 50) who were referred to the outpatient hypertension clinic and matched healthy subjects ( n = 10) are investigated. Results: Statistically significant changes ( p < 0.05 ANOVA, Fc > 1.5) of metabolites involved in central carbon, energy, and nitrogen metabolism are identified, especially purine and pyrimidine nucleosides and precursors, and free amino acids. PLS‐DA interpretation provides strong evidence of a disease‐specific metabolic pattern with dAMP, diiodothyronine, and 5‐methoxytryptophan as leading factors, and a sex‐specific metabolic pattern associated with orotidine 5‐phosphate, N‐acetylalanine, hydroxyproline, and cysteine. The results are verified using an independent sample set, which confirms the identification of specific signatures. Conclusions and clinical relevance: Metabolomics is used to identify low molecular weight molecular markers of PA, which paves the way for follow‐up validation studies in larger cohorts.